Non-Invasive Prenatal Testing Market - Snapshot

  • Non-invasive prenatal testing (NIPT) is a novel genetic screening method based on the analysis of cell-free fetal DNA in the maternal plasma.
  • The market for non-invasive prenatal testing is expanding significantly, worldwide, p rimarily due to increasing incidences of chromosomal aneuploidies among fetus, rising demand for early and non-invasive screening procedures, and rise in advanced maternal age (earlier 23 to 26 years has increased to 30 years).
  • The global non-invasive prenatal testing market was valued at US$ 1,300 Mn in 2018 and is anticipated to reach US$ 5,000 Mn by 2027, expanding at a CAGR of 16% from 2019
  • However, expansion of the global non-invasive prenatal testing market may be hampered in the near future by stringent regulatory guidelines. According to The American College of Obstetricians and Gynecologists (ACOG), Non-invasive prenatal testing should not be considered as routine laboratory testing, instead an informed patient choice post pre-test counselling.
  • In several countries, such as India and China, where a termination of female fetuses is considered illegal, implementation of Non-invasive prenatal testing has raised a serious ethical concern since these tests also help in sex determination of the fetus.
  • Consequently, regulatory guidelines and ethical issues are key factors that are projected to restraint the global Non-invasive prenatal testing market during the forecast period.
  • Major companies enter into distribution agreements to expand their footprint in the global non-invasive prenatal testing market.
  • Technological advancements and mergers & acquisitions are expected to propel the global non-invasive prenatal testing market during the forecast period.
non invasive prenatal testing nipt market 3
  • For instance, in July 2018, Berry Genetics partnered with 10X Genomics to upgrade non-invasive DNA prenatal testing. This collaboration was the first step for 10X Genomics to enter into the market in China. Additionally, in July 2016, Laboratory Corporation announced the acquisition of Sequenom for US$ 371 Mn, including debt. With this acquisition, Laboratory Corporation would strengthen its presence outside the U.S., in Europe and Asia Pacific, and enable it to provide top quality Non-invasive prenatal testing services.
  • Based on test type, the global non-invasive prenatal testing market has been classified into Materni21, Harmony, Panorama, Verifi, NIFTY, and others.
  • The MaterniT21 segment accounted for a significantly share of the global Non-invasive prenatal testing market in 2018. The segment is estimated to remain highly lucrative in the global non-invasive prenatal testing during the forecast period.
  • In terms of application, the global non-invasive prenatal testing market has been classified into trisomy, microdeletions symptoms, and others (Sex Chromosomes Disorders).
non invasive prenatal testing nipt market 2
  • The trisomy segment accounted for a prominent share of the Non-invasive prenatal testing market in Asia Pacific in 2018. Dominance of the trisomy segment is due to the increasing cases of Down’s Syndrome across worldwide.
  • Based on technology, the global non-invasive prenatal testing market has been classified into NGS (Next generation Sequencing), WGS (Whole Genome Sequencing) and others.
  • The NGS (next generation sequencing) segment accounted for a major share of the global Non-invasive prenatal testing market.
  • The segment is anticipated to exhibit a notable attractiveness index in the near future. Based on end-user, the global non-invasive prenatal testing market has been divided into hospitals, diagnostic laboratories, and others. Hospitals segment witnessed the maximum market share in the global non-invasive prenatal testing market in 2018.
  • In terms of revenue, North America dominated the global non-invasive prenatal testing market in 2018. High rate of diagnosis and treatment of trisomy disorders, strong healthcare infrastructure, and the presence of key companies in the U.S., are likely to drive the non-invasive prenatal testing market in North America during the forecast period.
  • On the other hand, developing healthcare infrastructure, high preference for non-invasive prenatal testing in China, and technological advancements are anticipated to boost the non-invasive prenatal testing market in Asia Pacific at a notable CAGR during the forecast period.
  • The report also provides profiles of leading players operating in the global non-invasive prenatal testing market.
    • Berry Genetics 
    • BGI
    • Laboratory Corporation of America Holdings
    • Agilent Technologies, Inc.
    • Illumina, Inc
    • Hoffmann-La Roche Ltd
    • NATERA, INC.
    • PerkinElmer Inc
    • Eurofins LifeCodexx AG
    • IGENOMIX. 
  • In February 2018, the India-based subsidiary of IGENOMIX transferred to a new big laboratory. The laboratory was also equipped with highly advanced instruments for gene sequencing, Ion S5 NGS systems, by Thermofisher.
  • In June 2017, LifeCodexx AG announced that the company entered to a partnership with Lifecell to introduce rapid and economic noninvasive DNA testing (PrenaTest qNIPT) in India. qNIPT, which identifies the presence of fetal trisomy 21 from maternal blood, received CE-IVD marking in December 2016.

Global Non-Invasive Prenatal Testing Market: Overview 

  • Non-invasive prenatal testing (NIPT) is a novel genetic screening method based on the analysis of cell-free fetal DNA in the maternal plasma.
  • The market for non-invasive prenatal testing is expanding significantly, worldwide, primarily due to increasing incidences of chromosomal aneuploidies among fetus, rising demand for early and non-invasive screening procedures, and rise in advanced maternal age (earlier 23 to 26 years has increased to 30 years).
  • The global non-invasive prenatal testing market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on test type, application, technology, end-user, and region.
  • A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market.
  • This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global non-invasive prenatal testing market. 

Global Non-Invasive Prenatal Testing Market: Key Segments 

  • Based on test type, the global non-invasive prenatal testing market has been classified into Materni21, Harmony, Panorama, Verifi, NIFTY, and others.
  • In terms of application, the global non-invasive prenatal testing market has been divided into Trisomy, Microdeletions symptoms, and others (sex chromosomes disorders).
  • Based on technology, the global non-invasive prenatal testing market has been classified into NGS (next generation sequencing), WGS (whole genome sequencing), and others.
  • In terms of end user, the global non-invasive prenatal testing market has been split into hospitals, diagnostic laboratories, and others.
  • The market size and forecast for each of these segments have been provided for the period from 2017 to 2027, along with their respective CAGRs for the forecast period from 2019 to 2027, considering 2018 as the base year. 

Global Non-Invasive Prenatal Testing Market: Regional Outlook

  • In terms of region, the global non-invasive prenatal testing market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Malaysia, Thailand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa and GCC Countries).
  • The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2017 to 2027, along with their respective CAGRs for the forecast period from 2019 to 2027, considering 2018 as the base year. The research study also covers the competitive scenario in these regions. 

Companies Mentioned in Report

  • The report also profiles the major players in the market in terms of attributes such as company overview, financial overview, Test Type, business strategies, and recent developments.
  • Major companies profiled in the global market are
    • Berry Genetics
    • BGI
    • Laboratory Corporation of America Holdings
    • Agilent Technologies, Inc.
    • Illumina, Inc
    • F. Hoffmann-La Roche Ltd
    • NATERA, INC.
    • PerkinElmer Inc
    • Eurofins LifeCodexx AG
    • IGENOMIX. 

The global non-invasive prenatal testing market has been segmented as follows:

Global Non-Invasive Prenatal Testing Market, by Test Type

  • Materni21
  • Harmony
  • Panorama
  • Verifi
  • NIFTY
  • Others 

Global Non-Invasive Prenatal Testing Market, by Application

  • Trisomy
  • Microdeletions Symptoms
  • Others (Including Sex Chromosomes Disorders) 

Global Non-Invasive Prenatal Testing Market, by Technology

  • NGS
  • WGS
  • Others 

Global Non-Invasive Prenatal Testing Market, by End-user

  • Hospitals
  • Diagnostic Laboratories
  • Others 

Global Non-Invasive Prenatal Testing Market, by Region

  • North America
    • U.S.
    • Canada 
  • Europe
    • Germany
    • U,K.
    • France
    • Spain
    • Italy
    • Rest of Europe 
  • Asia Pacific
    • China
    • Japan
    • India
    • Malaysia
    • Thailand
    • Rest of Asia Pacific 
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America 
  • Middle East & Africa
    • South Africa
    • GCC Countries
    • Rest of Middle East & Africa
.